Strategic funding Leverage the recent $21M funding and Series A activity as validation of the company’s growth trajectory to engage investors and potential partners around co-development and collaboration opportunities in precision oncology.

Clinical workflow SEngine is CLIA certified and focuses on functional screening, organoid cultures, and bioinformatics to tailor treatments; position solutions as tools to streamline oncologist workflows and improve patient-mpecific drug matching.

Data-driven partnerships The company emphasizes data accumulation to accelerate cancer treatments; propose data-sharing collaborations, biopharma partnerships, or contract research services that amplify pharma R&D with patient-derived data insights.

Technological edge With robotics, genomics, organoids, and PARIS and Oncosnipe-based collaborations via partners, there are opportunities to upsell integrated platform services, analytics, and access to live tumor cell testing outside patients.

Market positioning Target biotech and mid-to-large pharma with their clinical-focused, precision medicine model; highlight potential to accelerate drug discovery and patient stratification to differentiate offerings from larger incumbents.